Authors: Sunderland, SJ Sarasola, P Smith, DG Hellmann, K Radeloff, I Lusky, K Doberschutz, K Laskawy, E Rowan, TG

Citation: Sj. Sunderland et al., The clinical efficacy of danofloxacin 2.5% (Advocin (R)) in the treatment of Escherichia coli infections and in vitro activity against enteric pathogens in pigs., TIER UMSCH, 56(5), 2001, pp. 235

Authors: Radeloff, I Hellmann, K

Citation: I. Radeloff et K. Hellmann, Comparative efficacy of Flunixin in the treatment of bovine enzootic pneumonia of cattle, PRAKT TIER, 82(3), 2001, pp. 190

Authors: Sargent, JM Williamson, CJ Yardley, C Taylor, CG Hellmann, K

Citation: Jm. Sargent et al., Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562, BR J CANC, 84(7), 2001, pp. 959-964

Authors: Hellmann, K

Citation: K. Hellmann, Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: A critique, J CL ONCOL, 18(9), 2000, pp. 2004-2005

Authors: McTier, TL Siedek, EM Clemence, RG Wren, JA Bowman, DD Hellmann, K Holbert, MS Murphy, MG Young, DR Cruthers, LR Smith, DG Shanks, DJ Rowan, TG Jernigan, AD

Citation: Tl. Mctier et al., Efficacy of selamectin against experimentally induced and naturally acquired ascarid (Toxocara canis and Toxascaris leonina) infections in dogs, VET PARASIT, 91(3-4), 2000, pp. 333-345

Authors: Hellmann, K

Citation: K. Hellmann, Preventing the cardiotoxicity of anthracyclines by dexrazoxane - A real breakthrough, BR MED J, 319(7217), 1999, pp. 1085-1086